[go: up one dir, main page]

ME03417B - Composés de pladiénolide pyridine et leurs procédés d'utilisation - Google Patents

Composés de pladiénolide pyridine et leurs procédés d'utilisation

Info

Publication number
ME03417B
ME03417B MEP-2019-81A MEP201981A ME03417B ME 03417 B ME03417 B ME 03417B ME P201981 A MEP201981 A ME P201981A ME 03417 B ME03417 B ME 03417B
Authority
ME
Montenegro
Prior art keywords
processes
pyridine compounds
pladienolide pyridine
pladienolide
compounds
Prior art date
Application number
MEP-2019-81A
Other languages
German (de)
English (en)
Unknown language (me)
Inventor
Gregg F Keaney
John Wang
Baudouin Gerard
Kenzo Arai
Xiang Liu
Guo Zhu Zheng
Kazunobu Kira
Parcharee Tivitmahaisoon
Sudeep Prajapati
Nicholas C Gearhart
Yoshihiko Kotake
Satoshi Nagao
Sonobe Regina Kanada
Masayuki Miyano
Norio Murai
Silvia Buonamici
Lihua Yu
Betty Chan
Peter G Smith
Eunice Sun Park
Michael P Thomas
Ermira Pazolli
Kian Huat Lim
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53284528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03417(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of ME03417B publication Critical patent/ME03417B/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Pyridine Compounds (AREA)
MEP-2019-81A 2014-05-15 2015-05-13 Composés de pladiénolide pyridine et leurs procédés d'utilisation ME03417B (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461993423P 2014-05-15 2014-05-15
PCT/US2015/030464 WO2015175594A1 (fr) 2014-05-15 2015-05-13 Composés de pladiénolide pyridine et leurs procédés d'utilisation
EP15727125.5A EP3143016B1 (fr) 2014-05-15 2015-05-13 Composés de pladiénolide pyridine et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
ME03417B true ME03417B (fr) 2020-01-20

Family

ID=53284528

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-81A ME03417B (fr) 2014-05-15 2015-05-13 Composés de pladiénolide pyridine et leurs procédés d'utilisation

Country Status (36)

Country Link
US (1) US9481669B2 (fr)
EP (2) EP3143016B1 (fr)
JP (1) JP6067943B1 (fr)
KR (2) KR101710318B1 (fr)
CN (1) CN107074827B (fr)
AR (1) AR100431A1 (fr)
AU (1) AU2015259237B2 (fr)
BR (1) BR112016026638B1 (fr)
CA (1) CA2947754C (fr)
CL (1) CL2016002835A1 (fr)
CY (1) CY1121550T1 (fr)
DK (1) DK3143016T3 (fr)
ES (1) ES2712401T3 (fr)
HR (1) HRP20190432T1 (fr)
HU (1) HUE041838T2 (fr)
IL (1) IL248529B (fr)
JO (1) JO3668B1 (fr)
LT (1) LT3143016T (fr)
MA (1) MA39915B1 (fr)
ME (1) ME03417B (fr)
MX (2) MX373324B (fr)
MY (1) MY195081A (fr)
PE (1) PE20170384A1 (fr)
PH (1) PH12016502249B1 (fr)
PL (1) PL3143016T3 (fr)
PT (1) PT3143016T (fr)
RS (1) RS58400B1 (fr)
RU (1) RU2707730C2 (fr)
SG (1) SG11201609693XA (fr)
SI (1) SI3143016T1 (fr)
SM (1) SMT201900158T1 (fr)
TR (1) TR201902328T4 (fr)
TW (1) TWI634115B (fr)
UA (1) UA119458C2 (fr)
WO (1) WO2015175594A1 (fr)
ZA (1) ZA201607354B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3910073B1 (fr) 2015-09-01 2024-03-06 Eisai R&D Management Co., Ltd. Variants d'épissage associés à des mutants de sf3b1 néomorphes
IL259198B2 (en) * 2015-11-18 2023-04-01 Eisai R&D Man Co Ltd A solid form of paladinolide pyridine compound and methods of its use
EP3596235A1 (fr) 2017-03-15 2020-01-22 Eisai R&D Management Co., Ltd. Mutations de complexes d'épissage et leurs utilisations
BR112020008362A2 (pt) * 2017-10-31 2020-11-03 Eisai R&D Management Co., Ltd. composição farmacêutica, combinação, uso de uma combinação, e, método para tratar câncer.
TWI863903B (zh) * 2018-04-09 2024-12-01 日商衛材R&D企管股份有限公司 特定普拉二烯內酯化合物及其使用方法
SG11202009907XA (en) * 2018-04-12 2020-11-27 Eisai R&D Man Co Ltd Pladienolide derivatives as spliceosome targeting agents for treating cancer
CA3101205A1 (fr) * 2018-06-01 2019-12-05 Eisai R&D Management Co., Ltd. Procedes d'utilisation de modulateurs d'epissage
SG11202010341PA (en) 2018-06-01 2020-11-27 Eisai R&D Man Co Ltd Splicing modulator antibody-drug conjugates and methods of use
IL262658A (en) * 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
MX2022015374A (es) * 2020-06-05 2023-01-16 Eisai R&D Man Co Ltd Conjugados de anticuerpo anti antigeno de maduracion de linfocitos b (bcma)-farmaco y metodos de uso.
KR20230104204A (ko) 2020-11-04 2023-07-07 에자이 알앤드디 매니지먼트 가부시키가이샤 골수이형성 증후군(mds)에 대한 바이오마커 및 이를 사용하는 방법
WO2022263702A1 (fr) * 2021-06-18 2022-12-22 Universidad de Córdoba Composé pour le traitement du glioblastome
CN113876771B (zh) * 2021-11-12 2022-09-23 中国医学科学院基础医学研究所 一种靶向pabpc1的小分子药物及其在慢性髓系白血病中的应用
WO2023131866A1 (fr) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarqueurs pour le syndrome myélodysplasique (mds) et leurs méthodes d'utilisation
MA71743A (fr) 2022-11-07 2025-05-30 Eisai R&D Management Co., Ltd. Procédé de production d'un composé macrolide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312681B (en) 2001-02-01 2009-08-01 Novel physiologically active substance
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
JP4459051B2 (ja) 2002-07-31 2010-04-28 メルシャン株式会社 新規生理活性物質
CA2494536C (fr) 2002-07-31 2011-10-04 Mercian Corporation Substance active d'un macrolide cyclique a 12 chainons
WO2004037212A2 (fr) 2002-10-24 2004-05-06 Sepracor, Inc. Compositions contenant des derives du zopiclone, et leurs procedes de preparation et d'utilisation
AU2003284469B2 (en) 2002-11-29 2008-02-21 Eisai R&D Management Co., Ltd. Process for producing macrolide compound
WO2005052152A1 (fr) 2003-11-27 2005-06-09 Mercian Corporation Adn intervenant dans l'hydroxylation d'un compose macrolide
ATE466937T1 (de) 2003-11-28 2010-05-15 Kanagawa Kagaku Gijutsu Akad Verfahren zum nachweis von leberkrebs, diagnostikum für leberkrebs sowie heilmittel gegen krebs
JPWO2006003706A1 (ja) 2004-07-02 2008-04-17 株式会社プラスワンテクノ 組み合わせ計量技術
CA2574092C (fr) 2004-07-20 2011-08-23 Eisai R & D Management Co., Ltd. Adn codant pour un polypeptide participant a la biosynthese d'un pladienolide
TW200716744A (en) * 2005-05-26 2007-05-01 Eisai R&D Man Co Ltd Genetically modified microorganism and process for production of macrolide compound using the microorganism
CN102010403A (zh) 2005-10-13 2011-04-13 卫材R&D管理有限公司 普拉二烯内酯b和普拉二烯内酯d的全合成
EP2136209A4 (fr) * 2007-03-05 2010-10-27 Eisai R&D Man Co Ltd Procédé pour l'examen d'une action d'un agent anti-cancéreux utilisant un défaut d'épissage en tant que mesure
US20080312317A1 (en) 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives

Also Published As

Publication number Publication date
PL3143016T3 (pl) 2019-04-30
EP3143016A1 (fr) 2017-03-22
BR112016026638B1 (pt) 2022-08-02
CN107074827A (zh) 2017-08-18
JP6067943B1 (ja) 2017-01-25
CA2947754C (fr) 2024-01-02
KR20160082256A (ko) 2016-07-08
AU2015259237A1 (en) 2016-11-10
SG11201609693XA (en) 2016-12-29
ZA201607354B (en) 2018-05-30
ES2712401T3 (es) 2019-05-13
DK3143016T3 (en) 2019-04-08
AU2015259237B2 (en) 2019-08-15
HRP20190432T1 (hr) 2019-04-19
RS58400B1 (sr) 2019-04-30
EP3514154B1 (fr) 2022-08-03
MX2016014997A (es) 2017-06-29
HUE041838T2 (hu) 2019-05-28
KR101710318B1 (ko) 2017-02-24
LT3143016T (lt) 2019-06-10
SMT201900158T1 (it) 2019-05-10
AR100431A1 (es) 2016-10-05
PE20170384A1 (es) 2017-05-11
KR20170021899A (ko) 2017-02-28
TWI634115B (zh) 2018-09-01
BR112016026638A2 (fr) 2017-08-15
MA39915A (fr) 2017-03-22
KR102146726B1 (ko) 2020-08-21
TW201625596A (zh) 2016-07-16
TR201902328T4 (tr) 2019-03-21
RU2019124012A (ru) 2019-08-12
JO3668B1 (ar) 2020-08-27
IL248529B (en) 2019-11-28
MA39915B1 (fr) 2019-05-31
MY195081A (en) 2023-01-09
CL2016002835A1 (es) 2017-04-17
SI3143016T1 (sl) 2019-04-30
US20150329528A1 (en) 2015-11-19
MX373324B (es) 2020-05-04
NZ764190A (en) 2023-11-24
US9481669B2 (en) 2016-11-01
EP3143016B1 (fr) 2018-12-12
RU2016148887A3 (fr) 2018-12-11
CA2947754A1 (fr) 2015-11-19
JP2017505282A (ja) 2017-02-16
CN107074827B (zh) 2020-12-18
IL248529A0 (en) 2016-12-29
EP3514154A1 (fr) 2019-07-24
NZ725603A (en) 2023-11-24
MX388580B (es) 2025-03-20
PT3143016T (pt) 2019-02-27
CY1121550T1 (el) 2020-05-29
UA119458C2 (uk) 2019-06-25
PH12016502249B1 (en) 2023-12-13
WO2015175594A1 (fr) 2015-11-19
MX2020004476A (es) 2021-12-08
PH12016502249A1 (en) 2017-02-06
RU2707730C2 (ru) 2019-11-29
RU2016148887A (ru) 2018-06-18

Similar Documents

Publication Publication Date Title
MA39915A (fr) Composés de pladiénolide pyridine et leurs procédés d'utilisation
MA43827A (fr) Composés di-nucléotides cycliques et leurs procédés d'utilisation
EP3504213A4 (fr) Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation
EP3429635A4 (fr) Composés anti-crispr et leurs procédés d'utilisation
EP3380101A4 (fr) Composés inhibiteurs d'eif4-a et procédés associés
EP3359168A4 (fr) Composés thérapeutiques et procédés
MA49861A (fr) Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation
EP3665156A4 (fr) Composés, compositions et procédés
PL3558197T3 (pl) Wyroby chłonne zawierające laminaty zawierające elastomery wiązkowe
MA50063A (fr) Composés, compositions et procédés
MA43389A (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
EP2968440A4 (fr) Composés cytotoxiques et antimitotiques et leurs procédés d'utilisation
EP3337486A4 (fr) Composés deutérés et leurs utilisations
MA53145A (fr) Agents de liaison cd123 et leurs utilisations
PL3247791T3 (pl) Uniwersalne komórki nkt
EP3319612A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3319610A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3341027A4 (fr) Complexes de transfection et leurs procédés d'utilisation
EP3377060A4 (fr) Composés de pyrazole, procédés de production et utilisation
MA41296A (fr) Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
DK3341303T3 (da) Blisterpakning
MA49560A (fr) Composés cétoniques bicycliques et leurs procédés d'utilisation
EP3303436A4 (fr) Hydrofluorooléfines et leurs procédés d'utilisation
DK3286260T3 (da) Polyolefinrør
EP3350196A4 (fr) Composés carborane et leurs procédés d'utilisation